Cagrilintide
Comprehensive Research Analysis - Long-Acting Amylin Analog for Obesity
Classification: Long-Acting Amylin Receptor Agonist, Calcitonin Receptor Agonist Amino Acid Sequence: 37 amino acids (modified from human amylin) Chemical Formula: C₁₉₄H₃₁₂N₅₄O₅₉S₂ Molecular Weight: 4,409 Da Research Status: Phase III Clinical Trials (Active) WADA Status: Not Currently Prohibited
1. Executive Summary
Cagrilintide is a stabilized, lip
idated long-acting amylin analog developed by Novo Nordisk for treatment of obesity and type 2 diabetes. As a dual agonist of amylin receptors (AMYR) and calcitonin receptors (CTR), it produces sustained appetite suppression and gastric emptying delay, enabling once-weekly subcutaneous administration.
Phase 3 REDEFINE 1 Results: 22.7% weight loss at 68 weeks with CagriSema (cagrilintide 2.4mg + semaglutide 2.4mg), with 60% of patients achieving ≥20% weight loss. FDA Submission: December 2024 for CagriSema combination product.
Goal Relevance:
- I want to lose weight and manage my obesity effectively.
- I'm looking to control my appetite and reduce my food cravings.
- I need help managing my type 2 diabetes while also losing weight.
- I'm interested in a treatment that can help me achieve significant fat loss.
- I want to improve my metabolic health and support my weight management goals.
- I'm seeking a medication that offers long-term weight loss results.
- I need a solution for better blood sugar control alongside weight reduction.
2. Chemical Structure & Composition
Molecular Weight: 4,409 Da Formula: C₁₉₄H₃₁₂N₅₄O₅₉S₂ Structure: 37-amino acid peptide with:
- 14E/17R mutations (salt bridge stabilization)
- 25P/28P/29P mutations (reduced β-sheet/fibril formation)
- C-terminal proline (improved CTR potency)
- N-terminal C20 fatty acid (extended half-life via albumin binding)
Derived from rat amylin with human amylin modifications to prevent aggregation.
3. Mechanism of Action
Dual Receptor Agonism:
- Amylin Receptors (AMYR): Activates AMY1, AMY2, AMY3 in area postrema/hindbrain → appetite reduction
- Calcitonin Receptor (CTR): Enhances satiety signaling
Physiological Effects:
- Gastric Emptying Delay: Prolongs satiety post-meal
- Appetite Suppression: Central hypothalamic effects
- Glucagon Suppression: Improved glycemic control (mild)
Synergy with GLP-1 (Semaglutide): Complementary gut-brain axis modulation via separate pathways.
Goal Archetype Integration
Primary Goal Alignment
| Goal | Relevance | Role of Cagrilintide |
|---|---|---|
| Fat Loss | High | Primary indication; reduces food intake via satiety signaling, preserves lean mass while targeting fat mass reduction |
| Muscle Building | Low | Neutral to slightly protective; reduces relative fat mass while maintaining relative lean mass |
| Longevity | Moderate | Indirect via metabolic improvement; reduces obesity-related cardiometabolic disease risk |
| Healing/Recovery | None | No direct tissue repair mechanisms |
| Cognitive Optimization | Low | Indirect; weight loss may improve cognitive function in obese individuals |
| Hormone Optimization | Moderate | Improves insulin sensitivity, reduces glucagon; synergistic with metabolic hormone balance |
When This Compound Makes Sense
- Obesity with inadequate GLP-1 response: Patients who have plateaued on semaglutide/tirzepatide alone may benefit from the complementary amylin pathway
- Severe appetite dysregulation: Strong central satiety effects via area postrema activation target hedonic eating patterns
- Type 2 diabetes with obesity: Dual benefit of weight loss and glycemic control (HbA1c reduction up to 2.2% with CagriSema)
- Patients seeking combination therapy: CagriSema offers synergistic 20-23% weight loss vs. 12-15% with either agent alone
- GI-sensitive patients: Some individuals tolerate amylin analogs better than GLP-1 monotherapy
When to Choose Something Else
- Gastroparesis or severe GI disorders: Delayed gastric emptying effects are contraindicated
- History of medullary thyroid carcinoma or MEN2: Theoretical risk with long-acting amylin receptor agonists
- Active pancreatitis: Amylin analog theoretical risk
- Need for FDA-approved therapy: Cagrilintide remains investigational (NDA under review 2026)
- Cost-sensitive protocols: CagriSema combination expected to be premium-priced
- Patients requiring rapid results: Monotherapy achieves ~12% weight loss; combination therapy superior but still requires 68 weeks
4. Pharmacokinetics
Half-Life: 159–195 hours (~6.6–8.1 days; median 7.3 days) T_max: 24–72 hours Bioavailability: High (SC administration); specific % not disclosed Clearance: Dose-proportional exposure (AUC: 926–24,271 nmol×h/L; C_max: 6.14–170 nmol/L)
Long Duration: C20 fatty acid enables reversible albumin binding, slow release.
5. Dosing Protocols
Clinical Trial Dosing
Titration Schedule (Monotherapy):
- Weeks 1–2: 0.6 mg weekly
- Weeks 3–4: 1.2 mg weekly
- Weeks 5–6: 2.4 mg weekly
- Week 7+: 4.5 mg weekly (target dose)
CagriSema Combination:
- Fixed-dose: Cagrilintide 2.4 mg + Semaglutide 2.4 mg, once weekly
- Titration: 4-week ramp-up to full dose
Body Weight Adjustments: Not weight-based; fixed dosing used in trials.
Age-Stratified Dosing
| Age Bracket | Starting Dose | Adjustment | Rationale |
|---|---|---|---|
| 20-35 | 0.6 mg weekly | Standard titration | Full metabolic capacity; standard protocol |
| 35-50 | 0.6 mg weekly | Standard titration | No age-related adjustments in trials (mean age 52-58) |
| 50-65 | 0.6 mg weekly | Consider slower titration | May benefit from extended titration periods for GI tolerance |
| 65+ | 0.6 mg weekly | Slower titration; target lower maintenance dose | Slower clearance, increased sensitivity; emphasize muscle/bone preservation during weight loss |
Clinical Trial Demographics: Phase 2/3 trials included adults with no upper age limit, mean age 52-58 years. No specific dose adjustments published for elderly patients.
Important Consideration for Older Adults: Emphasis on resistance training for muscle strength and bone mineral density preservation during weight loss is critical. Substantial weight loss was observed even in participants who did not reach target dose, suggesting lower maintenance doses may be appropriate based on individual response.
Sex-Specific Considerations
Males:
- Standard dosing protocol applies
- May see greater absolute weight loss due to higher baseline body weight
- Monitor for changes in testosterone levels secondary to weight loss (typically improves)
Females:
- Standard dosing protocol applies
- Weight loss may affect menstrual regularity during active loss phase
- Pre-menopausal: Monitor for changes in cycle length/regularity
- Post-menopausal: No specific adjustments; may see additional metabolic benefits
- Pregnancy/Lactation: Contraindicated (unknown fetal effects)
6. Clinical Research & Evidence
Phase 2 Monotherapy (OASIS-1)
- N=706 overweight/obese adults
- Results: 2.4 mg → 9.7% weight loss; 4.5 mg → 10.8% weight loss vs. 3.0% placebo at 26 weeks
Phase 3 REDEFINE 1 (Obesity without Diabetes)
- Results: CagriSema 22.7% weight loss vs. 11.8% cagrilintide alone, 16.1% semaglutide alone, 2.3% placebo
- 60% achieved ≥20% weight loss; 23% achieved ≥30% weight loss
Phase 3 REDEFINE 2 (Type 2 Diabetes + Obesity)
- N=1,206 adults with T2D
- Results: Significant weight loss + HbA1c reduction (data pending full publication)
Phase 1b Combination Trial
- N=96 participants
- Results: 17.1% weight loss with cagrilintide 2.4mg + semaglutide 2.4mg at 20 weeks
7. Safety Profile
Common Side Effects:
- Nausea (most common; transient, dose-dependent)
- Vomiting
- Constipation (due to delayed gastric emptying)
- Injection site reactions
Severity: Predominantly mild-to-moderate; gastrointestinal effects diminish over time.
Serious Adverse Events: Low incidence; no major safety signals in Phase 2/3 trials.
Contraindications:
- Pregnancy/lactation (unknown fetal effects)
- Gastroparesis (worsens gastric stasis)
- Pancreatitis history (amylin analog theoretical risk)
- Personal/family history of medullary thyroid carcinoma or MEN2
Drug Interactions - Comprehensive
Prescription Medications
| Drug Class | Interaction | Severity | Management |
|---|---|---|---|
| Insulin | Increased hypoglycemia risk | Major | Reduce insulin dose 20-30% at initiation; monitor closely |
| Sulfonylureas | Additive hypoglycemia risk | Major | Consider dose reduction; monitor glucose frequently |
| Oral Diabetes Medications | Delayed absorption due to gastric emptying | Moderate | Take 30-60 min before cagrilintide; monitor efficacy |
| Warfarin | Altered absorption, variable INR | Moderate | Monitor INR more frequently; adjust as needed |
| Levothyroxine | Delayed/reduced absorption | Moderate | Take thyroid medication on empty stomach, 60+ min before cagrilintide |
| Oral Contraceptives | Potentially reduced absorption | Moderate | Consider barrier methods during initiation; monitor efficacy |
| Narrow Therapeutic Index Drugs | Variable absorption profiles | Moderate | Monitor drug levels; individualize timing |
Other Compounds (Stacking)
| Compound | Interaction | Effect | Recommendation |
|---|---|---|---|
| Semaglutide | Synergistic | 20-23% weight loss vs. 12-15% monotherapy | FDA-submitted combination (CagriSema); well-studied |
| Tirzepatide | Unknown/Not Recommended | Theoretical additive GI effects | Not studied together; avoid concurrent use |
| GLP-1 RAs (other) | Synergistic | Enhanced satiety, increased GI side effects | CagriSema is the studied combination |
| Pramlintide | Contraindicated | Overlapping amylin receptor activation | Do not combine amylin analogs |
| Metformin | Neutral to Synergistic | Complementary mechanisms | Generally well-tolerated together |
| SGLT2 Inhibitors | Neutral | Independent mechanisms | Can be combined safely |
Supplements
| Supplement | Interaction | Notes |
|---|---|---|
| Fat-soluble vitamins (A, D, E, K) | Reduced absorption | Take separately from cagrilintide; consider monitoring levels |
| Fish Oil/Omega-3 | Potentially reduced absorption | Take at different time of day |
| Fiber supplements | Additive GI effects | May worsen constipation; increase water intake |
| Protein powders | Neutral | Timing not critical |
| Electrolytes | Increased importance | Monitor during weight loss; supplement as needed |
Foods/Timing
| Food/Timing | Interaction | Notes |
|---|---|---|
| High-fat meals | Prolonged satiety, increased nausea | May worsen GI side effects initially |
| Large meals | Increased discomfort | Smaller, frequent meals recommended during titration |
| Alcohol | Enhanced hypoglycemia risk (if on diabetes meds) | Moderate consumption; avoid excess |
| Caffeine | Neutral | No known interaction |
| Meal timing | No restriction | Cagrilintide can be taken regardless of meals |
8. Administration & Practical Application
Route: Subcutaneous injection (abdomen, thigh, upper arm) Frequency: Once weekly Reconstitution: Supplied as lyophilized powder; reconstitute with bacteriostatic water Injection Technique: Rotate sites; use 27–30 gauge needle
Timing: No meal-time restrictions; consistent weekly schedule recommended.
Bloodwork Impact & Monitoring
Expected Marker Changes
| Marker | Expected Change | Direction | Timeline |
|---|---|---|---|
| HbA1c | 0.9-2.2% reduction (mono vs. combo) | ↓ | 12-26 weeks |
| Fasting Glucose | Mild-moderate reduction | ↓ | 4-12 weeks |
| Time in Range (TIR) | Increase from ~57% to 72-89% | ↑ | 12-26 weeks |
| Triglycerides | Mild reduction (secondary to weight loss) | ↓ | 12-26 weeks |
| LDL Cholesterol | Mild reduction expected | ↓ | 12-26 weeks |
| HDL Cholesterol | Neutral to mild increase | ↔/↑ | 12-26 weeks |
| Systolic Blood Pressure | Up to 13 mmHg reduction (CagriSema) | ↓ | 12-26 weeks |
| ALT/AST | May decrease with weight loss | ↓ | 12-26 weeks |
| GGT | May improve (fatty liver reduction) | ↓ | 26+ weeks |
| Insulin Levels | Decrease (improved sensitivity) | ↓ | 12-26 weeks |
| HOMA-IR | Improvement in insulin resistance | ↓ | 12-26 weeks |
Monitoring Schedule
| Timepoint | Required Tests | Optional Tests |
|---|---|---|
| Baseline | CBC, CMP, HbA1c, fasting lipid panel, thyroid panel | Fasting insulin, HOMA-IR, liver ultrasound |
| 4-6 weeks | Fasting glucose, renal function (if on diabetes meds) | HbA1c (if diabetic) |
| 12 weeks | HbA1c, CMP, lipid panel | Fasting insulin |
| 26 weeks | HbA1c, CMP, lipid panel, thyroid panel | Liver panel if baseline elevated |
| Ongoing (q3-6mo) | HbA1c, CMP, lipid panel | Vitamin levels (B12, D, fat-soluble) |
Red Flags in Labs
| Finding | Action |
|---|---|
| Lipase >3x ULN | Hold therapy; evaluate for pancreatitis |
| Severe hypoglycemia (<54 mg/dL) | Reduce concurrent diabetes medications |
| Creatinine elevation >30% | Evaluate hydration status; hold if dehydration |
| Potassium abnormalities | Address with supplementation; rule out dehydration |
| TSH changes | Evaluate thyroid medication timing/absorption |
| Severe GI symptoms + electrolyte derangement | Hold therapy; rehydrate; reassess |
Labs + Symptoms Integration
| Lab Finding | Symptom | Interpretation | Action |
|---|---|---|---|
| Normal glucose + persistent nausea | GI intolerance | Dose too high or rapid titration | Slow titration; reduce dose temporarily |
| Low glucose + tremors/sweating | Hypoglycemia | Concurrent diabetes med interaction | Reduce insulin/sulfonylurea dose |
| Elevated lipase + abdominal pain | Possible pancreatitis | Serious adverse event | Discontinue; urgent evaluation |
| Elevated creatinine + dizziness | Dehydration | Volume depletion from GI effects | IV fluids; hold therapy |
| Abnormal TSH + fatigue | Thyroid medication malabsorption | Delayed absorption of levothyroxine | Adjust timing; recheck in 6 weeks |
| Weight plateau + normal labs | Dose optimization needed | May benefit from dose increase or combination | Consider CagriSema if on monotherapy |
Marker-Based Dose Adjustment
Adjustment by Baseline Markers
| Baseline Marker | If High | If Low | If Normal |
|---|---|---|---|
| HbA1c (>8%) | Standard titration; expect greater improvement | N/A (not indicated for non-diabetics without obesity) | Standard protocol |
| BMI (>40) | May need full dose for efficacy | Consider lower maintenance | Standard protocol |
| eGFR (<60) | Conservative titration; monitor renal function | Standard protocol | Standard protocol |
| ALT/AST (>2x ULN) | Evaluate liver disease first; monitor closely | Standard protocol | Standard protocol |
Adjustment by Response Markers
| On-Treatment Finding | Adjustment |
|---|---|
| Good weight loss + good labs | Maintain current dose |
| Poor weight loss (<5% at 12 weeks) + good labs | May increase to maximum; consider CagriSema |
| Good response + mild GI symptoms | Continue; symptoms typically resolve |
| Persistent severe GI symptoms | Reduce dose; extend titration |
| Hypoglycemia events | Reduce concurrent diabetes medications first |
9. Storage & Stability
Lyophilized Powder:
- Store at -20°C to -80°C (long-term)
- Refrigerate 2–8°C (up to 6 months)
Reconstituted Solution:
- Refrigerate 2–8°C; use within 28 days (bacteriostatic water)
Protocol Integration
Stacking with Other Compounds
Common Stacks
| Stack | Rationale | Protocol Notes |
|---|---|---|
| Cagrilintide + Semaglutide (CagriSema) | Synergistic weight loss via separate GLP-1 and amylin pathways | FDA-submitted fixed-dose combination; 20-23% weight loss at 68 weeks |
| Cagrilintide + Metformin | Complementary insulin sensitization | No timing concerns; continue metformin at current dose |
| Cagrilintide + SGLT2 Inhibitor | Additive weight loss, cardiovascular/renal protection | Independent mechanisms; safe to combine |
| Cagrilintide + Testosterone (TRT) | Address metabolic syndrome; preserve lean mass during weight loss | Monitor hematocrit; standard TRT protocols apply |
Timing Considerations
| If Also Taking | Timing with Cagrilintide |
|---|---|
| Levothyroxine | Take thyroid medication 60+ min before cagrilintide on empty stomach |
| Oral diabetes meds | Take 30-60 min before cagrilintide dose |
| Warfarin | No specific timing; monitor INR closely |
| Other injectables (insulin) | Can inject at same time (different sites); reduce insulin dose 20-30% |
| Semaglutide (separate) | Use CagriSema fixed-dose if combining; not recommended as separate injections |
Contraindicated Combinations
| Do Not Combine With | Reason |
|---|---|
| Pramlintide | Overlapping amylin receptor activation; redundant mechanism |
| Other long-acting amylin analogs | Same mechanism class; no additive benefit |
| Tirzepatide | Not studied together; unpredictable GI effects and efficacy |
| Multiple GLP-1 RAs | Use only CagriSema as the studied GLP-1 combination |
Cagrilintide Monotherapy vs. CagriSema Combination
| Parameter | Cagrilintide Monotherapy | CagriSema Combination |
|---|---|---|
| Target Dose | 4.5 mg weekly | 2.4 mg + 2.4 mg weekly |
| Weight Loss (68 weeks) | 11.8% (REDEFINE 1) | 20.4-22.7% (REDEFINE 1) |
| HbA1c Reduction | 0.9% points | 2.2% points |
| Patients achieving ≥20% loss | ~25% | 60% |
| Patients achieving ≥25% loss | ~10% | 40% |
| GI Side Effects | Moderate | Higher (comparable to GLP-1 class) |
| Discontinuation Rate (AEs) | ~4% | ~6% |
| FDA Status | Investigational | NDA submitted Dec 2024 |
| Best For | GLP-1 intolerant patients; mild-moderate obesity | Maximum weight loss; T2D with obesity |
Integration with Pillars
| Pillar | Integration Point |
|---|---|
| Nutrition | High protein intake (1.2-1.6 g/kg) essential to preserve lean mass during weight loss; smaller, frequent meals improve GI tolerance; adequate hydration critical |
| Activity | Resistance training mandatory for older adults to preserve muscle/bone; aerobic exercise enhances metabolic benefits; exercise does not need timing around injection |
| Mindset | Set realistic expectations (12-23% weight loss over 68 weeks); GI side effects typically transient; weight loss rate varies individually; combination therapy may be needed for maximum results |
| Sleep | Improved sleep quality often accompanies weight loss; no direct sleep effects from cagrilintide |
| Recovery | No direct tissue repair effects; standard recovery protocols apply |
Protocol Decision Tree
START: Patient with obesity seeking pharmacotherapy
│
├─ GLP-1 naive or intolerant?
│ ├─ YES → Consider Cagrilintide monotherapy (different mechanism)
│ └─ NO → Continue to next question
│
├─ Already on GLP-1 with plateau?
│ ├─ YES → Consider switch to CagriSema (synergistic effect)
│ └─ NO → Continue to next question
│
├─ T2D with obesity requiring maximum efficacy?
│ ├─ YES → CagriSema preferred (2.2% HbA1c reduction + 20%+ weight loss)
│ └─ NO → Continue to next question
│
├─ Seeking FDA-approved therapy?
│ ├─ YES → Wait for CagriSema approval (expected 2026); use semaglutide/tirzepatide
│ └─ NO → Cagrilintide monotherapy or CagriSema (research context)
│
└─ GI sensitivity concerns?
├─ HIGH → Start with cagrilintide monotherapy; slower titration
└─ LOW → CagriSema for maximum efficacy
11. Product Cross-Reference
Core Peptides: Not currently listed. Epiq Aminos: Cagrilintide 10mg listed; pricing $150.
Chemical Validation: Molecular formula C₁₉₄H₃₁₂N₅₄O₅₉S₂, MW 4,409 Da matches PubChem CID 171397054.
12. References & Citations
- Frias JP, et al. Once-weekly cagrilintide for weight management. Lancet. 2021.
- Lau DCW, et al. Development of Cagrilintide. J Med Chem. 2021.
- Garvey WT, et al. Coadministered Cagrilintide-Semaglutide. NEJM. 2025.
- Novo Nordisk. FDA NDA Submission for CagriSema. Dec 2024.
- Cagrilintide lowers bodyweight through brain amylin receptors 1 and 3. eBioMedicine. 2025.
- Amylin: From Mode of Action to Future Clinical Potential in Diabetes and Obesity. PMC. 2025.
- REDEFINE 1 and REDEFINE 2 Trial Results. American College of Cardiology. 2025.
- Drug-Drug Interactions Between GLP-1 Receptor Agonists and Oral Medications. PMC. 2024.
- GLP-1RA-induced delays in gastrointestinal motility. Pharmacotherapy. 2025.
- Obesity pharmacotherapy in older adults: a narrative review. Int J Obes. 2024.
- Cagrilintide-Semaglutide in Adults with Overweight or Obesity and Type 2 Diabetes. NEJM. 2025.
- Cagrilintide Drug Information. DrugBank.
Document Version: 2.0 Last Updated: January 5, 2026 Development Status: Phase III Clinical Trials; NDA Under Review (CagriSema) For Research and Educational Purposes Only
Version History
- v2.0 (Jan 2026): Added Goal Archetype Integration, Age-Stratified Dosing, Comprehensive Drug Interactions, Bloodwork Impact Mapping, and Protocol Integration sections per ENHANCEMENT-TEMPLATE.md
- v1.0 (Dec 2025): Initial comprehensive research analysis